Advertisement

Pharmaceutical Research

, Volume 27, Issue 6, pp 979–988 | Cite as

Resveratrol Mobilizes Endogenous Copper in Human Peripheral Lymphocytes Leading to Oxidative DNA Breakage: A Putative Mechanism for Chemoprevention of Cancer

  • S. M. Hadi
  • M. F. Ullah
  • A. S. Azmi
  • A. Ahmad
  • U. Shamim
  • H. Zubair
  • H. Y. Khan
Expert Review

Abstract

Plant polyphenols are important components of human diet, and a number of them are considered to possess chemopreventive and therapeutic properties against cancer. They are recognized as naturally occurring anti-oxidants but also act as pro-oxidants catalyzing DNA degradation in the presence of metal ions such as copper. The plant polyphenol resveratrol confers resistance to plants against fungal agents and has been implicated as a cancer chemopreventive agent. Of particular interest is the observation that resveratrol has been found to induce apoptosis in cancer cell lines but not in normal cells. Over the last few years, we have shown that resveratrol is capable of causing DNA breakage in cells such as human lymphocytes. Such cellular DNA breakage is inhibited by copper specific chelators but not by iron and zinc chelating agents. Similar results are obtained by using permeabilized cells or with isolated nuclei, indicating that chromatin-bound copper is mobilized in this reaction. It is well established that tissue, cellular and serum copper levels are considerably elevated in various malignancies. Therefore, cancer cells may be more subject to electron transfer between copper ions and resveratrol to generate reactive oxygen species responsible for DNA cleavage. The results are in support of our hypothesis that anti-cancer mechanism of plant polyphenols involves mobilization of endogenous copper and the consequent pro-oxidant action. Such a mechanism better explains the anti-cancer effects of resveratrol, as it accounts for the preferential cytotoxicity towards cancer cells.

KEY WORDS

cancer comet assay endogenous copper pro-oxidant action resveratrol 

Notes

ACKNOWLEDGEMENT

The authors acknowledge the financial assistance provided by the University Grants Commission, New Delhi, under the DRS-II program.

Conflict of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

REFERENCES

  1. 1.
    Vainio H, Weiderpress E. Fruit and vegetables in cancer prevention. Nutr Cancer. 2006;54:111–42.CrossRefPubMedGoogle Scholar
  2. 2.
    Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, et al. Cancer chemopreventive activity of Resveratrol, a natural product derived from grapes. Science. 1997;275:218–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M, et al. Antiplatelet activity of synthetic and natural Resveratrol in red wine. Int J Tissue React. 1995;17:1–3.PubMedGoogle Scholar
  4. 4.
    Uenobe F, Nakamura S, Miyazama M. Antimutagenic effect of resveratrol against Trp-P-1. Mutat Res. 1997;373:197–200.PubMedGoogle Scholar
  5. 5.
    Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA. 1997;94:14138–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Hain R, Reif HJ, Krause E, Langebartels R, Kindl H, Vornam B, et al. Disease resistance results from foreign phytoalexin expression in a novel plant. Nature. 1993;361:153–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Sun NJ, Woo SH, Cassady JM, Snapka RM. Polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod. 1998;61:362–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 1998;421:277–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Fesus L, Szondy Z, Uray I. Probing the molecular program of apoptosis by cancer chemopreventive agents. J Cell Biochem. 1995;22(Suppl):151–61.CrossRefGoogle Scholar
  10. 10.
    Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res. 1997;57:1301–5.PubMedGoogle Scholar
  11. 11.
    Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signalling-dependent apoptosis in human tumor cells. Blood. 1998;92:996–1002.PubMedGoogle Scholar
  12. 12.
    Surh YJ, Hurh YJ, Kang JY, Lee E, Kong G, Lee SJ. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett. 1999;140:1–10.CrossRefPubMedGoogle Scholar
  13. 13.
    Inoue M, Suzuki R, Koide T, Sakaguchi N, Ogihara Y, Yabu Y. Antioxidant, gallic acid, induces apoptosis in HL60RG cells. Biochem Biophys Res Commun. 1994;204:898–904.CrossRefPubMedGoogle Scholar
  14. 14.
    Ahmad MS, Fazal S, Rahman A, Hadi SM, Parish JH. Activities of flavonoids for the cleavage of DNA in the presence of Cu(II): correlation wi±th the generation of active oxygen species. Carcinogenesis. 1992;13:605–8.CrossRefGoogle Scholar
  15. 15.
    Hadi SM, Asad SF, Singh S, Ahmad A. A putative mechanism for anticancer and apoptosis including properties of plant-derived polyphenolic compounds. IUBMB Life. 2000;50:1–5.CrossRefGoogle Scholar
  16. 16.
    Hadi SM, Bhat SH, Azmi AS, Hanif S, Shamim U, Ullah MF. Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for anticancer properties. Semin Cancer Biol. 2007;17:370–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Saiko P, Szakmary A, Jaeger W, Szekeres T. Reseveratrol and its analogs: defence against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res. 2008;658:68–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Saiko P, Szakmary A, Jaeger W, Szekeres T. Reseveratrol and its analogs: defence against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res. 2008;658:68–94.CrossRefPubMedGoogle Scholar
  19. 19.
    Bandele OJ, Clawson SJ, Osheroff N. Dietary polyphenols as Topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage. Chem Res Toxicol. 2008;21:1253–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Austin CA, Patel S, Ono K, Nakane H, Fischer LM. Site specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem J. 1992;282:883–9.PubMedGoogle Scholar
  21. 21.
    Smets KA. Programmed cell death (apoptosis) and the response to anticancer drugs. Anticancer Drugs. 1994;5:3–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst. 1997;89:1881–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Chang KL, Cheng HL, Huang LW, Hseih BS, et al. Combined effects of terazosin and genistein on a metastatic, hormone–independent human prostate cancer cell line. Cancer Lett. 2008;276:14–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms. Int J Oncol. 2003;23:17–28.PubMedGoogle Scholar
  25. 25.
    Ulrich S, Wolter F, Stein JM. Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol Nutr Food Res. 2005;49:452–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Shih A, Zhang S, Cao HJ, Boswell S, Wu YH, Tang HY, et al. Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol Cancer Ther. 2004;3:1355–64.PubMedGoogle Scholar
  27. 27.
    Li Y, Liu J, Liu X, Xing K, Wang Y, Li F, et al. Resveratrol–induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9. Appl Biochem Biotechnol. 2006;135:181–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Aziz MH, Reagan-Shaw S, Wu J, Longley BJ, Ahmad N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J. 2005;19:1193–5.PubMedGoogle Scholar
  29. 29.
    Kuo PL, Chiang LC, Lin CC. Resveratrol–induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci. 2002;72:23–34.CrossRefPubMedGoogle Scholar
  30. 30.
    Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS, et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther. 2006;5:621–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Kim YA, Lee WH, Choi TH, Rhee SH, Park KY, Choi YH. Involvement of p21/WAF1WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int J Oncol. 2003;23:1143–9.PubMedGoogle Scholar
  32. 32.
    Cecchinato V, Chiaramonte R, Nizzardo M, Cristofaro B, Basile A, Sherbet GV, et al. Resveratrol induced apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells. Biochem Pharmacol. 2007;74:1568–74.CrossRefPubMedGoogle Scholar
  33. 33.
    Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun. 1999;254:739–43.CrossRefPubMedGoogle Scholar
  34. 34.
    Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun. 1999;254:739–43.CrossRefPubMedGoogle Scholar
  35. 35.
    Aggarwal BB, Bhardwaj A, Aggarwal RS. Role of resveratrol in prevention and therapy of cancer: preclinincal and clinical studies. Anticancer Res. 2004;24:2783–840.PubMedGoogle Scholar
  36. 36.
    Brewer G. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Dis Today. 2005;10:1103–9.CrossRefGoogle Scholar
  37. 37.
    Goodman VL, Brewer GJ, Merajver SD. Copper deficiency as an anti-cancer strategy. Endocr Relat Cancer. 2004;11:255–63.CrossRefPubMedGoogle Scholar
  38. 38.
    Apelgot S, Coppey J, Fromentin A, Guille E, Poupon MF, Roussel A. Altered distribution of copper (64Cu) in tumorbearing mice and rats. Anticancer Res. 1986;6:159–64.PubMedGoogle Scholar
  39. 39.
    Semczuk B, Pomykalski M. Serum copper level in patients with laryngeal carcinoma. Otolaryngial Pol. 1973;27:17–23.Google Scholar
  40. 40.
    Tani P, Kokkola K. Serum iron, copper and iron binding capacity in bronchogenic pulmonary carcinoma. Scand J Res Dis. 1972;80:121–8.Google Scholar
  41. 41.
    Yucel I, Arpaci F, Ozet A, Doner B, Karayilanoglu T, Sayar A, et al. Serum copper and zinc and copper/zinc ratio in patients with breast cancer. Biol Trace Elem Res. 1994;40:31–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Habib FK, Dembinski TC, Stitch SR. The zinc and copper content of blood leukocytes and plasma from patients with benign and malignant prostates. Clin Chim Acta. 1980;104:329–35.CrossRefPubMedGoogle Scholar
  43. 43.
    Chan A, Wong F, Arumanayagam M. Serum ultrafiltrable copper, total copper and ceruloplasmin concentrations in gynecological carcinoma. Ann Clin Biochem. 1993;30:545–9.PubMedGoogle Scholar
  44. 44.
    Carpentieri U, Myers J, Thorpe L, Daeschner CW, Haggard ME. Copper, zinc and iron in normal and leukemic lymphocytes from children. Cancer Res. 1986;46:981–4.PubMedGoogle Scholar
  45. 45.
    Gupta SK, Shukla VK, Vaidya MP, Roy SK, Gupta S. Serum trace elements and Cu/Zn ratio in breast cancer patients. J Surg Oncol. 1991;46:178–81.CrossRefPubMedGoogle Scholar
  46. 46.
    Scanni A, Licciardello L, Trovato M, Tomirotii M, Biraghi M. Serum copper and ceruloplasmin levels in patients with neoplasias localized in the stomach, large intestine or lung. Tumori. 1977;63:175–80.PubMedGoogle Scholar
  47. 47.
    Rizk SL, Sky-Peck HH. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 1984;44:5390–4.PubMedGoogle Scholar
  48. 48.
    Margalioth EJ, Schenker JG, Chevion M. Copper and zinc levels in normal and malignant tissues. Cancer. 1983;52:868–72.CrossRefPubMedGoogle Scholar
  49. 49.
    Yaman M, Kaya G, Simsek M. Comparison of trace element concentrations in cancerous and noncancerous human endometrial and ovary tissues. Int J Gyn Cancer. 2007;17:200–28.Google Scholar
  50. 50.
    Kuo KW, Chen SF, Wu CC, Chen DR, Lee JH. Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res. 2002;89:1–11.CrossRefPubMedGoogle Scholar
  51. 51.
    Zuo XL, Chen JM, Zhou X, Li XZ, Mei GY. Levels of selenium, zinc, copper and antioxidant enzyme activity in patients with leukemia. Biol Trace Elem Res. 2006;114:41–54.CrossRefPubMedGoogle Scholar
  52. 52.
    Hrgovcic M, Tessmer CF, Thomas FB, Ong PS, Gamble JF, Shullenberger CC. Serum copper observations in patients with malignant lymphoma. Cancer. 1973;32:1512–24.CrossRefPubMedGoogle Scholar
  53. 53.
    Brewer G. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Dis Today. 2005;10:1103–9.CrossRefGoogle Scholar
  54. 54.
    Gali HU, Perchellet EM, Klish DS, Johnson JM, Perchellet JP. Hydrolyzable tannins: potent inhibitors of hydroperoxide production and tumor promotion in mouse skin treated with 12-O-tetradecanoyl phorbol-13–acetate in vivo. Int J Cancer. 1992;51:425–32.CrossRefPubMedGoogle Scholar
  55. 55.
    Khan NS, Hadi SM. Structural features of tannic acid important for DNA degradation in the presence of Cu(II). Mutagenesis. 1998;13:271–4.CrossRefPubMedGoogle Scholar
  56. 56.
    Rahman A, Shahabuddin A, Hadi SM, Parish JH. Complexes involving quercetin, DNA and Cu(II). Carcinogenesis. 1990;11:2001–3.CrossRefPubMedGoogle Scholar
  57. 57.
    Hanif S, Shamim U, Ullah MF, Azmi AS, Bhat SH, Hadi SM. The anthocyanidin delphinidin mobilizes endogenous copper ions from human lymphocytes leading to oxidative degradation of cellular DNA. Toxicology. 2008;249:19–25.CrossRefPubMedGoogle Scholar
  58. 58.
    Ullah MF, Shamim U, Hanif S, Azmi AS, Hadi SM. Cellular DNA breakage by soy isoflavone genistein and its methylated structural analogue biochanin A. Mol Nutr Food Res. 2009;(In press).Google Scholar
  59. 59.
    Ahmad A, Asad SF, Singh S, Hadi SM. DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation. Cancer Lett. 2000;154:29–37.CrossRefPubMedGoogle Scholar
  60. 60.
    Zheng LF, Wei QY, Cai YJ, Fang JG, Zhou B, Yang L, et al. DNA damage induced by resveratrol and its synthetic analogues in the presence of Cu(II) ions: mechanism and structure-activity relationship. Free Radic Biol Med. 2006;41:1807–16.CrossRefPubMedGoogle Scholar
  61. 61.
    Kagawa TF, Geierstanger BH, Wang AH, Ho PS. Covalent modification of guanine bases in double-stranded DNA: the 1:2-AZ-DNA structure of d(CGCGCG) in the presence of CuCl2. J Biol Chem. 1994;266:20175–84.Google Scholar
  62. 62.
    Bryan SE. Metal ions in biological systems. New York: Marcel Dekker; 1979.Google Scholar
  63. 63.
    Rahman A, Shahabuddin A, Hadi SM, Parish JH, Ainley K. Strand scission in DNA induced by quercetin and Cu(II): role of Cu(I) and oxygen free radicals. Carcinogenesis. 1989;10:1833–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Azmi AS, Bhat SH, Hanif S, Hadi SM. Plant polyphenols mobilize endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for anticancer properties. FEBS Lett. 2006;580:533–8.CrossRefPubMedGoogle Scholar
  65. 65.
    Czene S, Tiback M, Ringdahl MH. pH-dependant DNA cleavage in permeabilized human fibroblasts. Biochem J. 1997;323:337–41.PubMedGoogle Scholar
  66. 66.
    Barbouti A, Doulias PE, Zhu BZ, Feri B, Galaris D. Intracellular iron, but not copper plays a critical role in hydrogen peroxide-induced DNAdamage. Free Radic Biol Med. 2001;31:490–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Shamim U, Hanif S, Ullah MF, Azmi AS, Bhat SH, Hadi SM. Plant polyphenols mobilize nuclear copper in human peripheral lymphocytes leading to oxidatively generated DNA breakage: implications for an anticancer mechanism. Free Rad Res. 2008;(In press).Google Scholar
  68. 68.
    Long LH, Clement MV, Halliwell B. Artifacts in cell culture: rapid generation of hydrogen peroxide on addition of (−)-epigallocatechin, (−)-epigallocatechin gallate, (+)-catechin and quercetin to commonly used cell culture media. Biochem Biophys Res Commun. 2000;273:50–3.CrossRefPubMedGoogle Scholar
  69. 69.
    Bhat R, Hadi SM. DNA breakage by tannic acid –Cu(II): sequence specificity of the reaction and involvement of Cu(II). Mutat Res. 1994;313:39–48.PubMedGoogle Scholar
  70. 70.
    Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 1989;49:5870–8.PubMedGoogle Scholar
  71. 71.
    Radin NS. Designing anticancer drugs via the achilles heel: ceramide, allylic ketones, and mitochondria. Bioorg Med Chem. 2003;11:2123–42.CrossRefPubMedGoogle Scholar
  72. 72.
    Sellins KS, Cohen JJ. Gene induction by n-irradiation leads to DNA fragmentation in lymphocytes. J Immunol. 1987;139:3199–206.PubMedGoogle Scholar
  73. 73.
    Tsang WP, Chau SPY, Kong SK, Fung KP, Kwok TT. Reactive oxygen species mediated doxorubicin induced p53-independent apoptosis. Life Sci. 2003;73:2047–58.CrossRefPubMedGoogle Scholar
  74. 74.
    Ehrenfeld GM, Shipley JB, Heimbrook DC, Sugiyama H, Long EC, van Boom JH, et al. Copper dependent cleavage of DNA by bleomycin. Biochemistry. 1987;26:931–42.CrossRefPubMedGoogle Scholar
  75. 75.
    Azmi AS, Bhat SH, Hadi SM. Resveratrol–Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties. FEBS Lett. 2005;579:3131–5.CrossRefPubMedGoogle Scholar
  76. 76.
    Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Selverstone VJ, et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science. 1993;262:1274–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and antitumor promoter, induces apoptosis in human leukemia cells. Biochem Biophys Acta. 1996;1317:95–100.PubMedGoogle Scholar
  78. 78.
    Piwocka K, Zablocki K, Wieckowski MR, Skierski J, Feiga I, Szopa J, et al. A novel apoptosis-like pathway, independent of mitochondria and caspases, induced by curcumin in human lymphoblastoid T (Jurkat) cells. Exp Cell Res. 1999;249:299–307.CrossRefPubMedGoogle Scholar
  79. 79.
    Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001;2:589–98.CrossRefPubMedGoogle Scholar
  80. 80.
    Wolfe JT, Ross D, Cohen GM. A role for metals and free radicals in the induction of apoptosis in thymocytes. FEBS Lett. 1994;352:59–6.CrossRefGoogle Scholar
  81. 81.
    Held KD, Sylvester FC, Hopcia KL, Biaglow JE. Role of Fenton chemistry thiol-induced toxicity and apoptosis. Radiat Res. 1996;145:542–53.CrossRefPubMedGoogle Scholar
  82. 82.
    Swain J, Gutteridge JMC. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett. 1995;368:513–5.CrossRefPubMedGoogle Scholar
  83. 83.
    Satoh K, Kodofuku T, Sakagami H. Copper, but not iron, enhances apoptosis inducing activity of antioxidants. Anticancer Res. 1997;17:2487–90.PubMedGoogle Scholar
  84. 84.
    Burkitt MJ, Milne L, Nicotera P, Orrenius S. 1, 10-Phenanthroline stimulates internucleosomal DNA fragmentation in isolated rat liver nuclei by promoting redox activity of endogenous copper ions. Biochem J. 1996;313:163–9.PubMedGoogle Scholar
  85. 85.
    Ebadi M, Swanson S. The status of zinc, copper and metallothionein in cancer patients. Prog Clin Biol Res. 1988;259:161–75.PubMedGoogle Scholar
  86. 86.
    Margalioth EJ, Udassin R, Cohen C, Maor J, Anteby SO, Schenker JG. Serum copper level in gynecologic malignancies. Am J Obstet Gynecol. 1987;157:93–6.PubMedGoogle Scholar
  87. 87.
    Yoshida D, Ikeda Y, Nakazawa S. Quantitative analysis of copper, zinc and copper/zinc ratio in selective human brain tumors. J Neurooncol. 1993;16:109–15.CrossRefPubMedGoogle Scholar
  88. 88.
    Ebara M, Fukuda H, Hatano R, Saisho H, Nagato Y, Suzuki J, et al. Relationship between copper, zinc and metalothionein in hepatocellular carcinoma and its surrounding liver parenchyma. J Hepatol. 2000;33:415–22.CrossRefPubMedGoogle Scholar
  89. 89.
    Pizzolo G, Savarin T, Molino AM, Ambrosette A, Todeschini G, Vettore L. The diagnostic value of serum copper levels and other hematochemical parameters in malignancies. Tumorigenesis. 1978;64:55–61.Google Scholar
  90. 90.
    Yoshino M, Haneda M, Naruse M, Htay HH, Tsuboushi R, Qiao SL, et al. Prooxidant activity of curcumin: copper-dependent formation of 8-hydroxy-2-deoxyguanosine in DNA and induction of apoptotic cell death. Toxicol In Vitro. 2004;18:783–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Klein JA, Ackerman SL. Oxidative stress, cell cycle and neurodegenartion. J Clin Invest. 2003;111:785–93.PubMedGoogle Scholar
  92. 92.
    Oberly TD, Oberly LW. Antioxidant enzyme levels in cancer. Histol Histopathol. 1997;12:525–35.Google Scholar
  93. 93.
    Kong Q, Beel JA, Lilleihei KO. A threshold concept for cancer therapy. Med Hypothesis. 2000;55:29–35.CrossRefGoogle Scholar
  94. 94.
    Pryor WA. Why is hydroxyl radical the only radical that commonly adds to DNA? Hypothesis: it has rare combination of high electrophilicity, thermochemical reactivity and a mode of production near DNA. Free Radic Biol Med. 1988;4:219–33.CrossRefPubMedGoogle Scholar
  95. 95.
    Chevion M. Site-specific mechanism for free radical induced biological damage. The essential role of redox-active transition metals. Free Radic Biol Med. 1988;5:27–37.CrossRefPubMedGoogle Scholar
  96. 96.
    Chen ZP, Schell JB, Ho CT, Chen KY. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett. 1998;129:173–9.CrossRefPubMedGoogle Scholar
  97. 97.
    Gautam SC, Xu YX, Dumaguin M, Janakiraman N, Chapman RA. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant. 2000;25:649–5.CrossRefGoogle Scholar
  98. 98.
    Bertilli AA, Giovannini L, Stradi R, Bertelli A, Tillement JP. Plasma, urine and tissue levels of trans and cis-resveratrol (3, 40, 5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tissue React. 1996;18:67–71.Google Scholar
  99. 99.
    Asensi M, Medina I, Ortega A, Corretera J, Carmen-Bano M, Obrador E, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biol Med. 2002;33:387–98.CrossRefGoogle Scholar
  100. 100.
    de TM kok, van Breda SG, Manson MM. Mechanisms of combined action of different chemopreventive dietary compounds: a review. Eur J Nutr. 2008;2:51–9.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • S. M. Hadi
    • 1
  • M. F. Ullah
    • 1
  • A. S. Azmi
    • 2
  • A. Ahmad
    • 2
  • U. Shamim
    • 1
  • H. Zubair
    • 1
  • H. Y. Khan
    • 1
  1. 1.Department of Biochemistry, Faculty of Life SciencesAligarh Muslim UniversityAligarhIndia
  2. 2.Department of Pathology, Karmanos Cancer InstituteWayne State University School of MedicineDetroitUSA

Personalised recommendations